source: American Academy of Neurology
Jon Tinsley, Francesco Muntoni, Stefan Spinty, Helen Roper, Imelda Hughes, Valeria Ricotti, Alison Bracchi, Bina Tejura, David Roblin, Gary Layton, Kay Davies
To assess the safety, tolerability and pharmacokinetics of SMT C1100; the first ever utrophin modulator molecule to enter clinical trials for Duchenne muscular dystrophy (DMD) patients.
In DMD skeletal muscle is lost due to an inability to produce dystrophin. During foetal muscle development utrophin takes the functional role of dystrophin. Continuous muscle expression of utrophin could functionally replace dystrophin and potentially overcome the dystrophin deficit in DMD. In dystrophic animal studies, daily SMT C1100 treatment significantly reduced muscle degeneration leading to improved muscle function. A Phase 1, double-blind, placebo-controlled study has been completed in healthy male subjects with data supportive of SMT C1100 moving into DMD patient trials.
This was a multi-centre Phase 1, open-label, single and multiple oral dose, safety, tolerability and pharmacokinetic study in 12 male DMD patients aged between 6 and 11 years. A sequential group design was chosen and three groups consisting of 4 patients were sequentially dosed at 50 mg/kg bid, 100mg/kg bid and 100mg/kg tid orally.
All oral doses of SMT C1100 were safe and well tolerated in paediatric DMD patients. The most frequently reported adverse events following dosing was pale faeces, considered related to study drug and mild in severity. There were no clinically significant findings in laboratory evaluations, vital signs, ECGs or physical examinations during the study. SMT C1100 was rapidly absorbed, but exhibited high between-patient variability with a number of boys achieving lower systemic exposures than anticipated. In the majority of the boys, serum biomarkers indicative of muscle damage decreased during the dosing phase.
Data from this trial has helped to design the next SMT C1100 trial in DMD boys which looks at the effect of diet on drug absorption and allows muscle damage biomarker observations to be assessed under placebo controlled conditions.
Alder Hey Children’s NHS Foundation Trust, UK; Birmingham Heartlands Hospital, UK; Paramstat Ltd., UK; Royal Manchester Children’s Hospital, UK; Summit (Oxford) Ltd., UK; Summit Therapeutics Inc., USA; UCL Institute of Child Health, UK; University of Oxford, UK